Ernexa Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ERNA research report →
Price Chart
About the company
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases.
- CEO
- Sanjeev Luther
- IPO
- 1991
- Employees
- 5
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on ERNA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.30M
- P/E
- -0.08
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.49
- EV/EBITDA
- 0.15
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -332.12%
- ROIC
- -271.22%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-9,319,000
- Net Income
- $-14,084,000+68.4%
- EPS
- $-56.00-42.7%
- OCF Growth
- +55.7%
- FCF Growth
- +56.5%
- 52W High
- $37.50
- 52W Low
- $1.32
- 50D MA
- $2.49
- 200D MA
- $5.37
- Beta
- 2.74
- RSI (14)
- 24
- Avg Volume
- 43.90K
No earnings-call transcripts are available for ERNA yet.
- Free Float
- 70.0%
- Shares Outstanding
- 1.69M
- Float Shares
- 1.18M
of shares held by institutions
9 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 35.92K | ▲ 24.77K |
| Corient Private Wealth LP | 17.46K | ▲ 17.46K |
| Geode Capital Management, LLC | 16.08K | ▲ 16.08K |
| Vanguard Fiduciary Trust Co | 8.34K | 0 |
| Vanguard Capital Management LLC | 5.68K | 0 |
| Tradewinds Capital Management, LLC | 4.61K | ▲ 4.25K |
| Tower Research Capital LLC (Trc) | 1.55K | ▲ 1.55K |
| Morgan Stanley | 200 | ▲ 200 |
| Citigroup Inc | 102 | ▲ 102 |
| Blackrock, Inc. | 33 | 0 |
| Ubs Group AG | 19 | ▲ 19 |
| Bnp Paribas Financial Markets | 1 | 0 |
Held by 5 ETFs
Biggest fund positions in ERNA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 14, 26 | Spiegel Robert J. | other | 0 |
| Aug 31, 26 | Bristol James Arthur | other | 8,320 |
| Aug 31, 26 | Bristol James Arthur | other | 5,083 |
| Aug 31, 26 | Cicala Peter | other | 5,943 |
| Aug 31, 26 | Cicala Peter | other | 5,083 |
| Aug 31, 26 | Polinsky David | other | 5,083 |
| Aug 31, 26 | Wexler William A. | other | 5,943 |
| Aug 31, 26 | Ratner Elena | other | 5,944 |
| Aug 31, 26 | Luther Sanjeev | other | 118,848 |
| Feb 10, 26 | Polinsky David | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ERNA coverage
Recent articles, reports, and earnings notes.
No research on ERNA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ERNA report →Ernexa Therapeutics Highlights ERNA-101's Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment
globenewswire.com · Oct 22
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
globenewswire.com · Oct 12
Ernexa Therapeutics' ERNA-101 Selected for Flash Talk Presentation at Nature Conferences' Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
globenewswire.com · Oct 6
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
globenewswire.com · Oct 1
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
globenewswire.com · Sep 30
Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
globenewswire.com · Sep 29
Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D.
globenewswire.com · Sep 17
Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing
globenewswire.com · Sep 15
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.